Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1

Molecular Oncology

Volumn 7, Issue 4, 2013, Pages 826-839

  Karagiannis, George S ^a,b   Berk, Aaron ^a   Dimitromanolakis, Apostolos ^b   Diamandis, Eleftherios P ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bone morphogenetic protein; Cancer associated fibroblasts; Colorectal cancer; Desmoplasia; Gremlin 1; Migration

Indexed keywords

GREMLIN 1; PROTEOME; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CELL ASSAY; CELL DIFFERENTIATION; CELL FATE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MATHEMATICAL MODEL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ALPHA-SMOOTH MUSCLE ACTIN; AMERICAN TYPE CULTURE COLLECTION; ATCC; BMP(I); BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN (INHIBITOR); CAF; CANCER INVASION FRONT; CANCER-ASSOCIATED FIBROBLAST; CANCER-ASSOCIATED FIBROBLASTS; CIF; COL12A1; COLLAGEN TYPE XII; COLORECTAL CANCER; CRC; DESMOPLASIA; DESMOPLASTIC PROTEIN DATASET; DMEM; DPD; DULBECCO'S MODIFIED EAGLE'S MEDIUM; ECM; EMT; EPITHELIAL-TO-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FBS; FETAL BOVINE SERUM; FOLLISTATIN; FOLLISTATIN-LIKE 3; FST; FSTL3; GENE ONTOLOGY; GO; GREM1; GREMLIN-1; HEPATOCYTE GROWTH FACTOR; HGF; HIGH TEMPERATURE REQUIREMENT A3; HTRA3; INGENUITY PATHWAY ANALYSIS; INGENUITY PATHWAY KNOWLEDGEBASE; IPA; IPKB; LOX; LYSINE-6-OXIDASE; MIGRATION; PDGF; PLATELET-DERIVED GROWTH FACTOR; TGF-Β; TRANSFORMING GROWTH FACTOR-BETA; UPA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR (RECEPTOR-2); VEGF(R2); Α-SMA;

CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR;

EID: 84880723873     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.04.002     Document Type: Article

References (69)

1. Alarcon T., Byrne H.M., Maini P.K. A cellular automaton model for tumour growth in inhomogeneous environment. J.Theor. Biol. 2003, 225:257-274.
2. Alarmo E.L., Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr. Relat. Cancer 2010, 17:R123-R139.
3. Anderson A.R. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math. Med. Biol. 2005, 22:163-186.
4. Ayala G., Tuxhorn J.A., Wheeler T.M., Frolov A., Scardino P.T., Ohori M., et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 2003, 9:4792-4801.
5. Beck S.E., Jung B.H., Del Rosario E., Gomez J., Carethers J.M. BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK. Cell. Signal. 2007, 19:1465-1472.
6. Beck S.E., Jung B.H., Fiorino A., Gomez J., Rosario E.D., Cabrera B.L., et al. Bone morphogenetic protein signaling and growth suppression in colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G135-G145.
7. Beites C.L., Hollenbeck P.L., Kim J., Lovell-Badge R., Lander A.D., Calof A.L. Follistatin modulates a BMP autoregulatory loop to control the size and patterning of sensory domains in the developing tongue. Development 2009, 136:2187-2197.
8. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
9. Carvajal G., Droguett A., Burgos M.E., Aros C., Ardiles L., Flores C., et al. Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant. Proc. 2008, 40:734-739.
10. Chaplain M.A., Anderson A.R. Mathematical modelling, simulation and prediction of tumour-induced angiogenesis. Invasion Metastas. 1996, 16:222-234.
11. Coveney P.V., Fowler P.W. Modelling biological complexity: a physical scientist's perspective. J.R. Soc. Interface 2005, 2:267-280.
12. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123:2229-2238.
13. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. J.Pathol. 2003, 200:429-447.
14. De Wever O., Pauwels P., De Craene B., Sabbah M., Emami S., Redeuilh G., et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem. Cell. Biol. 2008, 130:481-494.
15. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N.Engl. J. Med. 1986, 315:1650-1659.
16. Elenbaas B., Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell. Res. 2001, 264:169-184.
17. Flier S.N., Tanjore H., Kokkotou E.G., Sugimoto H., Zeisberg M., Kalluri R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J.Biol. Chem. 2010, 285:20202-20212.
18. Glaros T., Larsen M., Li L. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front. Biosci. 2009, 14:3988-3993.
19. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
20. Hardwick J.C., Van Den Brink G.R., Bleuming S.A., Ballester I., Van Den Brande J.M., Keller J.J., et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004, 126:111-121.
21. He X.C., Zhang J., Tong W.G., Tawfik O., Ross J., Scoville D.H., et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat. Genet. 2004, 36:1117-1121.
22. Heit B., Kubes P. Measuring chemotaxis and chemokinesis: the under-agarose cell migration assay. Sci. STKE 2003, 2003:PL5.
23. Hewitt R.E., Leach I.H., Powe D.G., Clark I.M., Cawston T.E., Turner D.R. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int. J. Cancer 1991, 49:666-672.
24. Hsu M.Y., Rovinsky S., Penmatcha S., Herlyn M., Muirhead D. Bone morphogenetic proteins in melanoma: angel or devil?. Cancer Metastasis Rev. 2005, 24:251-263.
25. Huang W.H., Chang M.C., Tsai K.S., Hung M.C., Chen H.L., Hung S.C. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2012, Oct 22. 10.1038/onc.2012.458.
26. Jensen L.J., Kuhn M., Stark M., Chaffron S., Creevey C., Muller J., et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009, 37:D412-D416.
27. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
28. Karagiannis G.S., Pavlou M.P., Diamandis E.P. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol. Oncol. 2010, 4:496-510.
29. Karagiannis G.S., Petraki C., Prassas I., Saraon P., Musrap N., Dimitromanolakis A., et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012, 3:267-285.
30. Karagiannis G.S., Poutahidis T., Erdman S.E., Kirsch R., Riddell R.H., Diamandis E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical Pressure on cancer tissue. Mol. Cancer Res. 2012, 10:1403-1418.
31. Karagiannis G.S., Weile J., Bader G.D., Minta J. Integrative pathway dissection of molecular mechanisms of moxLDL-induced vascular smooth muscle phenotype transformation. BMC Cardiovasc. Disord. 2013, 13:4.
32. Kosinski C., Li V.S., Chan A.S., Zhang J., Ho C., Tsui W.Y., et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc. Natl. Acad. Sci. U S A 2007, 104:15418-15423.
33. Kotzsch A., Nickel J., Seher A., Heinecke K., van Geersdaele L., Herrmann T., et al. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J.Biol. Chem. 2008, 283:5876-5887.
34. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression?. Histol. Histopathol. 2002, 17:599-621.
35. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part II): functional impact on tumor tissue. Histol. Histopathol. 2002, 17:623-637.
36. Maere S., Heymans K., Kuiper M. BiNGO: a cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21:3448-3449.
37. Materi W., Wishart D.S. Computational systems biology in cancer: modeling methods and applications. Gene Regul. Syst. Bio. 2007, 1:91-110.
38. Merico D., Isserlin R., Bader G.D. Visualizing gene-set enrichment results using the cytoscape plug-in enrichment map. Methods Mol. Biol. 2011, 781:257-277.
39. Merico D., Isserlin R., Stueker O., Emili A., Bader G.D. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010, 5:e13984.
40. Mitola S., Ravelli C., Moroni E., Salvi V., Leali D., Ballmer-Hofer K., et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010, 116:3677-3680.
41. Mitrovic B., Schaeffer D.F., Riddell R.H., Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod. Pathol. 2012, 25:1315-1325.
42. Mueller L., Goumas F.A., Affeldt M., Sandtner S., Gehling U.M., Brilloff S., et al. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am. J. Pathol. 2007, 171:1608-1618.
43. Namkoong H., Shin S.M., Kim H.K., Ha S.A., Cho G.W., Hur S.Y., et al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 2006, 6:74.
44. Navab R., Strumpf D., Bandarchi B., Zhu C.Q., Pintilie M., Ramnarine V.R., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl. Acad. Sci. U S A 2011, 108:7160-7165.
45. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
46. Pandol S., Edderkaoui M., Gukovsky I., Lugea A., Gukovskaya A. Desmoplasia of pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2009, 7:S44-S47.
47. Perumpanani A.J., Sherratt J.A., Norbury J., Byrne H.M. Biological inferences from a mathematical model for malignant invasion. Invasion Metastas. 1996, 16:209-221.
48. Prassas I., Karagiannis G.S., Batruch I., Dimitromanolakis A., Datti A., Diamandis E.P. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol. Cancer Ther. 2011, 10:2083-2093.
49. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272.
50. R Development Core Team R: A Language and Environment for Statistical Computing 2008, R Foundation for Statistical Computing, Vienna, Austria. http://www.r-project.org.
51. Ravelli C., Mitola S., Corsini M., Presta M. Involvement of alpha(v)beta (3) integrin in gremlin-induced angiogenesis. Angiogenesis 2012, 16:235-243.
52. Ridgway D., Broderick G., Ellison M.J. Accommodating space, time and randomness in network simulation. Curr. Opin. Biotechnol. 2006, 17:493-498.
53. Sherratt J.A., Chaplain M.A. A new mathematical model for avascular tumour growth. J.Math. Biol. 2001, 43:291-312.
54. Silva A.S., Gatenby R.A., Gillies R.J., Yunes J.A. A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ. J.Theor. Biol. 2009, 262:601-613.
55. Sneddon J.B., Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 2007, 1:607-611.
56. Sneddon J.B., Zhen H.H., Montgomery K., van de Rijn M., Tward A.D., West R., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. U S A 2006, 103:14842-14847.
57. Stabile H., Mitola S., Moroni E., Belleri M., Nicoli S., Coltrini D., et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 2007, 109:1834-1840.
58. Stover C. Dual role of complement in tumour growth and metastasis (Review). Int. J. Mol. Med. 2010, 25:307-313.
59. Sun S., Wheeler M.F., Obeyesekere M., Patrick C.W. A deterministic model of growth factor-induced angiogenesis. Bull. Math. Biol. 2005, 67:313-337.
60. Tiger C.F., Krause F., Cedersund G., Palmer R., Klipp E., Hohmann S., et al. A framework for mapping, visualisation and automatic model creation of signal-transduction networks. Mol. Syst. Biol. 2012, 8:578.
61. Tocharus J., Tsuchiya A., Kajikawa M., Ueta Y., Oka C., Kawaichi M. Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-beta signaling. Dev. Growth Differ. 2004, 46:257-274.
62. Ward J.P., King J.R. Mathematical modelling of avascular-tumour growth. IMA J. Math. Appl. Med. Biol. 1997, 14:39-69.
63. Ward J.P., King J.R. Mathematical modelling of avascular-tumour growth. II: modelling growth saturation. IMA J. Math. Appl. Med. Biol. 1999, 16:171-211.
64. Wen X.Z., Akiyama Y., Baylin S.B., Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006, 25:2666-2673.
65. Wu W.K., Sung J.J., Wu Y.C., Li Z.J., Yu L., Cho C.H. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br. J. Pharmacol. 2008, 154:632-638.
66. Xing F., Saidou J., Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 2010, 15:166-179.
67. Yang F., Tuxhorn J.A., Ressler S.J., McAlhany S.J., Dang T.D., Rowley D.R. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005, 65:8887-8895.
68. Ye L., Lewis-Russell J.M., Kyanaston H.G., Jiang W.G. Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol. Histopathol. 2007, 22:1129-1147.
69. Zeisberg M., Shah A.A., Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J.Biol. Chem. 2005, 280:8094-8100.